Ansofaxine

Ansofaxine hydrochloride (INN) (former developmental code names LY03005, LPM570065), also known as 4-methylbenzoate desvenlafaxine hydrochloride, is a serotonin-norepinephrine-dopamine reuptake inhibitor that is under development by Luye Pharma Group for the treatment of major depressive disorder. It is described as an SNDRI and prodrug to desvenlafaxine. However, unlike desvenlafaxine, which has in vitro IC₅₀ values of 53 nM and 538 nM for inhibition of serotonin and norepinephrine reuptake, respectively, ansofaxine has respective in vitro IC₅₀ values of 723 nM, 763 nM, and 491 nM for serotonin, norepinephrine, and dopamine reuptake inhibition. As of March 2015, the drug is in phase I clinical trials.